Filing Flows › Comparisons › ABEO vs STOK
Abeona Therapeutics vs Stoke Therapeutics: ABEO and STOK compared
Abeona Therapeutics is the larger company: $11.4M of revenue in its latest quarter (Q2 2026) against $11.3M for Stoke Therapeutics (Q3 2026). Abeona Therapeutics is growing faster (28× against +6% a year earlier). Abeona Therapeutics is more profitable, with an operating margin of -120.0% against -686.9%.
Where the money goes: ABEO and STOK
Abeona Therapeutics (ABEO) · Q2 2026
Abeona Therapeutics, Q2 2026: revenue $11.4M (28× year over year), operating margin -120.0%, net loss $20.2M, operating cash flow −$17.5M. The chart follows the revenue to costs, profit and cash.
Stoke Therapeutics (STOK) · Q3 2026
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
| Abeona Therapeutics (ABEO) | Stoke Therapeutics (STOK) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $11.4M | $11.3M |
| Revenue growth, Y/Y | 28× | +6% |
| Operating margin | -120.0% | -686.9% |
| Net earnings | −$20.2M | −$73.6M |
| Net margin | -177.4% | -654.3% |
| Operating cash flow | −$17.5M | −$62.7M |
Questions
Which is bigger, Abeona Therapeutics or Stoke Therapeutics?
Abeona Therapeutics is the larger company: $11.4M of revenue in its latest quarter (Q2 2026) against $11.3M for Stoke Therapeutics (Q3 2026).
Is Abeona Therapeutics or Stoke Therapeutics growing faster?
Abeona Therapeutics is growing faster (28× against +6% a year earlier).
Which is more profitable, Abeona Therapeutics or Stoke Therapeutics?
Abeona Therapeutics is more profitable, with an operating margin of -120.0% against -686.9%.
More: Abeona Therapeutics earnings · how Abeona Therapeutics makes money · Stoke Therapeutics earnings · how Stoke Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.